In addition to the drawback of being dosed BID in a qD world, Isentress is evidently uncompetitive with other first-line HIV drugs on price. According to this PR from the AIDS Healthcare Foundation (an advocacy group for AIDS patients), the yearly price of Isentress for self-pay patients is $12,900* (~$35/day). This is about 3x the price of other commonly used first-line agents and it is additive to the prices of the other two drugs first-line patients must take as part of a 3-drug cocktail:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.